| 查看: 659 | 回复: 1 | |||
pkupku金虫 (正式写手)
|
[交流]
英国伦敦国王学院KCL招收博士生(高分子,生物医学方向)
|
|
感兴趣可联系:Adrian Najer教授本人, adrian.najer@kcl.ac.uk PhD programme candidate positions in antipathogenic nanomedicines or fundamental nanotherapeutic analysis at King’s College London, UK (potential start dates: Fall 2025) Broadly applicable therapeutics for viral and parasi1c diseases are urgently needed. Nanomedicine offers a unique opportunity to create therapeutics that function by inhibiting host cell interactions. The first project I can offer is centred around the synthesis, analysis, and testing of such advanced antipathogenic nanotherapeutics. The second project encompasses detailed analysis of protein fouling on vesicle-type nanomedicines. This phenomenon, also called protein corona formation, is one key factor currently hindering widespread translation of nanomedicines to the clinic. Hence, fundamental studies and incorporating nanomedicine design changes to allow adsorption of preferred proteins but repelling of undesirable components will be part of that second project. There are two suitable PhD schemes open at the moment, CSC (100% at KCL) and KCL-HKU (joint programme, 50% at each location), and I will consider candidates for both. Please indicate in your email which one you are interested in. PhD schemes: - K-CSC (internal deadline 1st January 2025): hHps://www.kcl.ac.uk/study-legacy/funding/kings-china-scholarship-council-phd-scholarship-programme-k-csc - KCL-HKU joint PhD (deadline 2nd March 2025): hHps://www.kcl.ac.uk/study-legacy/funding/joint-phd-scholarship If interested, please send an email + CV to: adrian.najer@kcl.ac.uk hHps://scholar.google.com/cita2ons?user=K7JUcVIAAAAJ&hl=en&oi=ao |
» 猜你喜欢
有时候真觉得大城市人没有县城人甚至个体户幸福
已经有12人回复
依托企业入选了国家启明计划青年人才。有无高校可以引进的。
已经有11人回复
依托企业入选了国家启明计划青年人才。有无高校可以引进的。
已经有10人回复
同年申请2项不同项目,第1个项目里不写第2个项目的信息,可以吗
已经有9人回复
表哥与省会女结婚,父母去帮带孩子被省会女气回家生重病了
已经有7人回复
天津大学招2026.09的博士生,欢迎大家推荐交流(博导是本人)
已经有9人回复
有院领导为了换新车,用横向课题经费买了俩车
已经有10人回复
AI 太可怕了,写基金时,提出想法,直接生成的文字比自己想得深远,还有科学性
已经有6人回复
» 本主题相关商家推荐: (我也要在这里推广)

| 1 |
2楼2024-12-08 09:52:02













回复此楼